<DOC>
	<DOCNO>NCT02126709</DOCNO>
	<brief_summary>Importance This proof concept study - whereby hypothesize Repigel may represent paradigm shift global acne treatment . Historically , dearth clinical evidence use povidone-iodine inflammatory acne . This likely due stain related iodine use , acceptable consumer . The trial drug , Povidone Iodine , however , become colourless odourless matter second application skin . This represent ideal product may perform test look efficacy management acne . A mainstay pathogenesis acne involve overgrowth proliferation skin micro-organism , primarily proprionibacterium Acnes . Long term antibiotic therapy usually prescribed period 3 6 month . Previous study reveal form antibiotic therapy ineffective , patient usually poorly compliant , also result formation antibiotic resistant micro-organism , turn reduces treatment efficacy . Potential Benefits As , Povidone Iodine antiseptic property represent promising avenue elimination Proprionibacterium Acnes without associate problem long term antibiotic use , development antibiotic-resistance . It cosmetically acceptable , affordable , easy use .</brief_summary>
	<brief_title>The Efficacy Safety 3 % Povidone-Iodine Acne Therapy</brief_title>
	<detailed_description>Aim This proof concept study - determine efficacy safety Povidone Iodine treatment acne . Methodology This single centre , double blind , randomize control trial . There 2 arm 15 patient 2 month study period . Follow Week 0 , Week 2 , Week 4 , Week 6 , Week 8 3 . Capture baseline demographic . Age b . Sex c. Race d. Lesion count - total , inflammatory , non-inflammatory e. FDA score 4 . Efficacy evaluation . 5 point IGA score b . Total lesional count c. No . inflammatory lesion d. No . non-inflammatory lesion e. Photography ( +- ) f. Scoring Cardiff Acne Disability Index . 5 . Safety Evaluation . Score itchiness b . Score scale c. Score erythema d. Score pain 6 . Primary end point - a. percentage reduction lesion count week 0 week 8 i. total lesion count ii . total inflammatory count iii . total non-inflammatory count b . Proportion subject IGA score 0 1 week 8 c. Time 50 % reduction total lesion count 7 . Secondary end point . Improvement Cardiff Acne Disability Index Povidone Iodine apply face patient use finger tip - onto acne affect area face .</detailed_description>
	<mesh_term>Povidone-Iodine</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<mesh_term>Povidone</mesh_term>
	<criteria>1 . Patients diagnose mild moderate inflammatory acne grade 2 3 . 2 . Patients must least 12 year age 3 . No gender preference male female allow 4 . Subjects provide sign dated write voluntary inform consent 1 . Thyroid Dysfunction 2 . Pregnancy , Breast feed 3 . History hypersensitivity iodine 4 . History renal impairment 5 . Using OCPs 6 . Using concurrent medication know exacerbate acne 7 . Nodulocystic acne severe variant 8 . Had facial procedure chemical laser peel microdermabrasion 2 week study 9 . No topical antiacne product 2 week prior study commencement till conclusion . 10 . No systemic corticosteroid 4 week prior study start 11 . No systemic retinoids 3 month prior study start 12 . No concurrent use tan booth sunbathe 13 . Any condition judgement investigator may place person unacceptable risk participation 14 . Any subject participate another clinical trial 30 day study entry ,</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Povidone Iodine</keyword>
	<keyword>Safety</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Acne treatment</keyword>
</DOC>